This study is looking at two different ways to give buprenorphine (Zubsolv) to people with moderate to severe opioid use disorder (OUD) who come to the emergency department (ED) and are not currently receiving medication for OUD. You would receive either a standard dose or a higher dose of Zubsolv. Researchers want to see if one dose helps more people start and stay in OUD treatment within 10 days. They will also compare withdrawal symptoms, cravings, and use of other drugs between the two groups. To join, you must be 18-65 years old, in the ED during screening hours, meet criteria for moderate to severe OUD, and have clear signs of opioid withdrawal (COWS score of 8 or higher). The study aims to enroll 360 participants.

Study design

This is a randomized study where you would be assigned by chance to one of two groups, and neither you nor the study staff would know which dose you are receiving (double-blind, double-dummy). It plans to include 360 participants.

What's involved

You would receive 3 buprenorphine pills and be observed for 2 hours, with your withdrawal symptoms checked at 1 and 2 hours. You would also receive a referral for ongoing OUD treatment and a prescription for 16 mg of buprenorphine daily.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured within 10 days after you are randomly assigned to a treatment group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.